Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ: ARCT )

27.49 -0.90 (-3.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 Next >
United Therapeutics, Super Micro Computer, Novo Nordisk And Other Big Gainers From Wednesday
U.S. stocks closed lower on Wednesday, with the Dow Jones dropping more than 500 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session
Gainers Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results. 
Via Benzinga
Why Arcturus Therapeutics Stock Is Skyrocketing Today
Investors are applauding Arcturus' collaboration with CSL. 
Via The Motley Fool
Where Arcturus Therapeutics Stands With Analysts
Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Why Is Rogers Corporation (ROG) Stock Down 44% Today?
Rogers Corporation (ROG) stock is falling hard on Wednesday following confirmation that DuPont (DD) no longer plans to acquire the company. 
Via InvestorPlace
Why Is Benefitfocus (BNFT) Stock Up 48% Today?
Benefitfocus (BNFT) stock is rocketing higher on Wednesday as investors react to a $570 million acquisition deal with Voya Financial (VOYA). 
Via InvestorPlace
Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?
The run-up in ARCT stock is practically unstoppable as two science-focused firms collaborate to develop mRNA technology. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Upgrades 
Via Benzinga
Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines
 
Via Benzinga
BARDA Backs Arcturus' Influenza Vaccine Program
 
Via Benzinga
What 4 Analyst Ratings Have To Say About Arcturus Therapeutics
Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million. 
Via Benzinga
Why Rogers Shares Are Trading Sharply Lower; Here Are 33 Stocks Moving Premarket
Gainers Avinger, Inc. (NASDAQ: AVGR) rose 32% to $1.36 in pre-market trading. Avinger is expected to release its financial results for the third quarter on Wednesday, November 9, 2022. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, trader! It's time to take a look at all of the latest news behind the biggest pre-market stock movers on Thursday! 
Via InvestorPlace
Arcturus' COVID-19 Booster Shows Durability Against Omicron Variants
 
Via Benzinga
Match Group, Super Micro Computer And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
7 Small-Cap Stocks to Buy on the Dip or You’ll Be Kicking Yourself Later
With the market taking a dip and possibly poised to incur more red ink, these are the small-cap stocks to buy that appeal to contrarians. 
Via InvestorPlace
4 Analysts Have This to Say About Arcturus Therapeutics
  Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings: 
Via Benzinga
Recap: Arcturus Therapeutics Q2 Earnings
  Arcturus Therapeutics (NASDAQ:ARCT) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Expert Ratings for Arcturus Therapeutics
Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
  
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
What 6 Analyst Ratings Have To Say About Arcturus Therapeutics
Over the past 3 months, 6 analysts have published their opinion on Arcturus Therapeutics (NASDAQ:ARCT) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
93 Biggest Movers From Yesterday
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... 
Via Benzinga
70 Stocks Moving In Monday's Mid-Day Session
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
Upgrades 
Via Benzinga
70 Biggest Movers From Friday
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for... 
Via Benzinga
Arcturus Therapeutics's Earnings Outlook
Arcturus Therapeutics (NASDAQ:ARCT) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) provided updated data from its Phase 1/2 booster clinical trial showing the durability of antibody response with ARCT-154 for at least three months... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.